Skip to main content

Scleroderma clinical trials at UCLA

2 in progress, 0 open to eligible people

Showing trials for
  • Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

    Los Angeles, California and other locations

  • Platform Clinical Study for Conquering Scleroderma

    Sorry, not yet accepting patients

    The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

    Los Angeles, California and other locations

Our lead scientists for Scleroderma research studies include .

Last updated: